Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03373461 |
|
Recruitment Status :
Completed
First Posted : December 14, 2017
Last Update Posted : July 9, 2021
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | December 29, 2020 |
| Actual Study Completion Date : | June 22, 2021 |
| Certification/Extension First Submitted : | July 7, 2021 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
June 14, 2022 |